Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived ``off the shelf'' stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications.
Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived ``off the shelf'' stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications.
There are no open picks with this stock at the moment.
Picks
There are no open picks with this stock at the moment.
Sponsored Links
Ride Momentum Stocks to Quick Gains!
The market is finally breaking out, creating the perfectd wave for investing in momentum stocks. Zacks is the king of fundamental analysis, but this service also uses technical indicators for the best possible timing. Click here to learn more >>.
Find Winning Stocks Quickly with Research Wizard, a powerful desktop software program. Start with easy-to-use pre-loaded strategies, then develop your own. Backtest against years of historical data to see how your approach works in any market. Start a Free Trial Today >>
With Zacks Method for Trading you'll transform yourself into a Master Stock Trader, one simple step at a time. Get step-by-step instructions and learn how to use the 28% per year Zacks Rank system to find market-beating stocks on your own, fully exploiting the system that beat the market 18 of the last 20 years. Find out how >>
Stock screening and chart patterns expert, Kevin Matras, combs through the best Zacks stock-picking strategies averaging +60% yearly gains to find stocks with charts showing they are ready to skyrocket. Chart Patterns Trader >>
